

Dr. Vinay Chopra  
MD (Pathology & Microbiology)  
Chairman & Consultant Pathologist

Dr. Yugam Chopra  
MD (Pathology)  
CEO & Consultant Pathologist

NAME : Mrs. SWETA KUMARI  
AGE/ GENDER : 25 YRS/FEMALE  
COLLECTED BY :  
REFERRED BY : LOOMBA HOSPITAL (AMBALA CANTT)  
BARCODE NO. : 01513504  
CLIENT CODE. : KOS DIAGNOSTIC LAB  
CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

PATIENT ID : 1555184  
REG. NO./LAB NO. : 012407200052  
REGISTRATION DATE : 20/Jul/2024 01:17 PM  
COLLECTION DATE : 20/Jul/2024 01:21 PM  
REPORTING DATE : 21/Jul/2024 11:24 AM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

## ENDOCRINOLOGY

### QUADRUPLE MARKER MATERNAL SCREENING

#### QUADRUPLE MARKER

##### PATEINT SPECIFICATIONS

DATE OF BIRTH	28-06-1997		
MATERNAL AGE	27.5	YEARS	
WEIGHT	80	Kg	
ETHNIC ORIGIN	ASIAN		ASIAN
H/O IVF	ABSENT		
H/O INSULIN DEPENDANT DIABETES	ABSENT		
H/O SMOKING	ABSENT		
H/O TRISOMY 21 SCREENING	ABSENT		

##### ULTRA SOUND SCAN DETAILS

DATE OF ULTRASOUND by ULTRASOUND SCAN	20-07-2024		
METHOD FOR GESTATION AGE ESTIMATION by ULTRASOUND SCAN	ULTRASOUND SCAN DETAILS		
FOETUS (NOS) by ULTRASOUND SCAN	1		
GA ON THE DAY OF SAMPLE COLLECTION by ULTRASOUND SCAN	16.6	WEEKS	
BIPARIETAL DIAMETER (BPD) by ULTRASOUND SCAN	32.5	mm	26 - 52

##### QUADRUPLE TEST - BIOCHEMICAL MARKERS

ALPHA FETO PROTEIN (AFP) PRENATAL SCREENING: SERUM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	27.8	ng/mL	
ESTRIOL (uE3) UNCONJUGATED by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	1.12	ng/mL	
BETA HCG by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	30347	mIU/mL	



DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist


<b>NAME</b>	: Mrs. SWETA KUMARI	<b>PATIENT ID</b>	: 1555184
<b>AGE/ GENDER</b>	: 25 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012407200052
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 20/Jul/2024 01:17 PM
<b>REFERRED BY</b>	: LOOMBA HOSPITAL (AMBALA CANTT)	<b>COLLECTION DATE</b>	: 20/Jul/2024 01:21 PM
<b>BARCODE NO.</b>	: 01513504	<b>REPORTING DATE</b>	: 21/Jul/2024 11:24 AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
INHIBIN A <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	138.6	pg/mL	
<b><u>MULTIPLE OF MEDIAN (MOM) VALUES</u></b>			
AFP MOM <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	0.87		
ESTRIOL (uE3) MOM <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	0.96		
BETA HCG MOM <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	1.19		
INHIBIN A MOM <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	1.08		
<b><u>TRISOMY 21 SCREENING (DOWNS SYNDROME) RISK ASSESSMENT</u></b>			
TRISOMY 21 SCREENING RISK RESULT <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	NEGATIVE (-ve)		NEGATIVE (-ve)
TRISOMY 21 AGE RISK <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	1:4205 NEGATIVE (-ve)		
TRISOMY 21 BIOCHEMICAL RISK <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	1:1208 NEGATIVE (-ve)		RISK CUT OFF 1:270
<b><u>TRISOMY 18 SCREENING RISK ASSESSMENT</u></b>			
TRISOMY 18 AGE RISK <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	NEGATIVE (-ve)		
TRISOMY 18 SCREENING RISK <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	< 1:10000 NEGATIVE (-ve)		RISK CUT OFF 1:100
<b><u>NEURAL TUBE DEFECTS SCREENING RISK ASSESSMENT</u></b>			
NEURAL TUBE DEFECT SCREENING RISK <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	NEGATIVE (-ve)		RISK CUT OFF 1:50
SPINA BIFIDA/ANENCEPHALY SCREENING RISK <i>by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)</i>	< 1:10000 NEGATIVE (-ve)		RISK CUT OFF 1:50

**INTERPRETATION:**

- Multiple marker serum has become standard tool used in obstetric care to identify pregnancies that may have increased risk for certain birth defects such as NEURAL TUBE DEFECTS (NTD'S), DOWN'S SYNDROME (TRISOMY 21) AND TRISOMY 18. The screen is performed by measuring analytes in maternal serum that are produced by the fetus and the placenta. The analytes values along with maternal demographic information such as age, weight, gestational age, diabetic status, and race are used together in mathematical model to derive risk estimate.
- The laboratory establishes a specific cut off for each condition, which classifies each screen as either screen-positive or screen-negative.
- A screen-positive result indicates that the value obtained exceeds the established cut off.



  
**DR. VINAY CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
**DR. YUGAM CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Mrs. SWETA KUMARI	<b>PATIENT ID</b>	: 1555184
<b>AGE/ GENDER</b>	: 25 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012407200052
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 20/Jul/2024 01:17 PM
<b>REFERRED BY</b>	: LOOMBA HOSPITAL (AMBALA CANTT)	<b>COLLECTION DATE</b>	: 20/Jul/2024 01:21PM
<b>BARCODE NO.</b>	: 01513504	<b>REPORTING DATE</b>	: 21/Jul/2024 11:24AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

4. The estimated risk calculation and screen results are dependant on accurate information for gestation, maternal age, race, IDD, and weight. Inaccurate information can lead to significant alterations in the estimated risk. In particular, erroneous assessment of gestational age can result in false-positive or false-negative screen results. Because of its increased accuracy, we therefore recommend determination of gestational age by ultrasound, rather than by last menstrual period (LMP), When possible.

*4. A negative screen indicates a lower probability of having a baby with TRISOMY 21, TRISOMY 18 and NEURAL TUBE DEFECTS, but does not completely exclude the possibility.*

*5. A positive screen on the contrary only indicates a higher probability of having a baby with TRISOMY 21, TRISOMY 18 and NEURAL TUBE DEFECTS, and needs confirmation by cytogenetic studies and/or level II scan.*

**NOTE:**

1. Triplet and higher multiple pregnancies cannot be interpreted
2. The reportable range for Trisomy 21, Trisomy 18 and NTD : >1:50 to < 1:10000
3. TRISOMY 21: HIGH RISK: >1:50 - 1:250
4. TRISOMY 18: HIGH RISK: >1:50 - 1:100
5. NEURAL TUBE DEFECT (NTD'S): HIGH RISK: >1:50
6. Biological markers evaluated in this test have marked as H(HIGH) or L(LOW) since there is wide variation in Alpha Fetoprotein, HCG and Unconjugated Estriol ranges depending upon gestational age. "In Range" and "Out of Range" columns are not applicable for the parameters appearing in Multiple of Median (MoM) and Risk calculation.
7. Individually, Alpha Fetoprotein or HCG or unconjugated Estriol levels do not correlate with risk assessment of Trisomy 18, Trisomy 21 or Neural Tube Defects

\*\*\* End Of Report \*\*\*



*Dr. Vinay Chopra*

DR. VINAY CHOPRA  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

*Dr. Yugam Chopra*

DR. YUGAM CHOPRA  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)




**Result Down's syndrome screening**

Name	MRS. SWETA KUMARI	Sample ID	2407220896/AMB	diabetes	no
Patient ID		D.O.B.	28/06/1997	Fetuses	1
Day of serum taking	20/07/2024	Age at delivery	27.5	Smoker	no
Date of report:	21/07/2024	Weight [kg]	80 kg	IVF	no
Previous trisomy 21 pregnancies	no			Ethnic origin	Asian

**Corrected MoM's and calculated risks**

AFP	27.8	ng/ml	0.87	Corr. MoM	Gestational age at sample date	16 + 6
uE3	1.12	ng/ml	0.96	Corr. MoM	determination method	BPD Hadlock
HCG	30347	mIU/ml	1.19	Corr. MoM	Physician	
Inh-A	138.6	pg/ml	1.08	Corr. MoM		



**Tr.21 risk**  
at term  
1:4205

**Age risk**  
at term  
1:1208

**Down's Syndrome Risk**

**The calculated risk for Trisomy 21 is below the cut off which represents a low risk.**

After the result of the Trisomy 21 test it is expected that among 4205 women with the same data, there is one woman with a trisomy 21 pregnancy and 4204 women with not affected pregnancies.  
The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician.  
Please note that risk calculations are statistical approaches and have no diagnostic value!

**Neural tube defects risk**

**The corrected MoM AFP (0.87) is located in the low risk area for neural tube defects.**

**Risk for trisomy 18**

**The calculated risk for trisomy 18 is < 1:10000, which indicates a low risk.**

below cut off

Below Cut Off, but above Age Risk

above cut off

Prisca 5.2.0.13